Chan Wan Tsun Adrian Alan
Independent Non-Executive Director

Chan Wan Tsun Adrian Alan, Australian, was appointed as an Independent Non-Executive Director of the Company since 21 April 2023.  Mr Chan was graduated from the University of New South Wales, Australia with a bachelor degree in commerce in accounting and finance in April 2000. He has been a member of CPA Australia and the Hong Kong Institute of Certified Public Accountants since June 2006 and November 2009 respectively.
 
Mr Chan has over 24 years of experience in accounting, financial management and corporate finance. He started his career with Deloitte Touche Tohmatsu and worked in the audit department of the firm from January 2000 to March 2000. Mr Chan then worked in various financial institutions and investment banks between April 2000 and November 2009, including DBS Vickers Securities, with his last position as an executive in the corporate finance department, from April 2000 to December 2001, DBS Asia Capital Limited, with his last position as assistant vice president in equity capital markets, wholesale banking-global financial markets from January 2002 to July 2005, and UOB Asia (Hong Kong) Limited, with his last position as associate director, from July 2005 to November 2009.

After leaving UOB Asia (Hong Kong) Limited in November 2009, Mr Chan switched his career from corporate finance to financial management. From November 2009 to June 2015, he was the chief financial officer of Enviro Energy International Holdings Limited, a company listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) (stock code: 1102), where he was responsible for overall financial management, internal control function and accounting function. From November 2011 to June 2021, Mr Chan served as an independent non-executive director of Grand Baoxin Auto Group Limited, a company listed on the Main Board of the Stock Exchange (stock code: 1293). Since July 2015, Mr Chan has served as the chief financial officer of Sun Ray Capital Investment Corporation, a private investment company based in Hong Kong; since July 2018, Mr Chan has served as the chief financial officer of LabyRx Immunologic Therapeutics Limited, a bio-medical company focused on developing a comprehensive platform for treating adenocarcinomas; since August 2018, Mr Chan has served as the chief financial officer of Lifespans Limited, a medical device start-up company; and since January 2021, Mr Chan has served as a regional director of The CFO (HK) Limited, a company providing part-time chief financial officers.
 
Mr Chan is an independent non-executive director of Cheerwin Group Limited (a company listed on the Main Board of the Stock Exchange (stock code: 6601)) and Best Linking Group Holdings Limited (a company listed on the GEM Board of the Stock Exchange (stock code: 8617)).